Table 4 Sigmoidoscopy score distribution at parent study baseline, upon entry to the maintenance phase (month 0) and at 12 months
Sigmoidoscopy scoreMMX mesalazine 2.4 g/day (given once daily)MMX mesalazine 2.4 g/day (1.2 g given twice daily)
Efficacy population n = 219 (% patients)“Per-protocol” population n = 171 (% patients)Efficacy population n = 232 (% patients)“Per-protocol” population n = 191 (% patients)
Parent study baseline
    0 (normal)0000
    1 (mild)18.718.112.511.5
    2 (moderate)74.977.280.681.7
    3 (severe)6.44.76.96.8
Month 0
    0 (normal)66.266.158.659.7
    1 (mild)33.833.941.440.3
    2 (moderate)0000
    3 (severe)0000
Month 12
    0 (normal)57.158.556.959.7
    1 (mild)21.522.221.620.9
    2 (moderate)3.22.93.42.6
    3 (severe)0.501.72.1
    missing17.816.416.414.7